Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: Updated results from a phase III trial (CheckMate 238).
Jeffrey S. Weber(NYU Langone Health), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Ana Arance(Hospital Clínic de Barcelona), Mario Mandalà(University of Perugia), Michele Maio(University of Siena), C. Lance Cowey(Texas Oncology), Michael Schenker(Sorbonne Université), Vanna Chiarion‐Sileni(Centre Hospitalier Universitaire Brugmann), Mark R. Middleton(University of Oxford), Veerle de Pril(Inserm), Jean‐Jacques Grob(Aix-Marseille Université), Iván Márquez‐Rodas(Hospital General Universitario Gregorio Marañón), Stéphane Dalle(Hospices Civils de Lyon), James Larkin(Trinity College Dublin), Victoria Atkinson(The University of Queensland), Reinhard Dummer(University Hospital of Zurich), Helen Gogas(National and Kapodistrian University of Athens), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Anila Qureshi(Bristol-Myers Squibb (United States)), Marcus O. Butler(University of Toronto)
Cited by 75
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2019|3.7k